UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D. C. 20549
FORM 12b-25
NOTIFICATION OF LATE FILING
SEC FILE NUMBER 000-54808
CUSIP NUMBER 67021R 10 4
(Check One) [ ] Form 10-K [ ] Form 20-F [ ] Form 11-K [X] Form 10-Q [ ]
Form N-SAR [ ] Form N-CSR
For the Period Ended June 30, 2024
[ ] Transition Report on Form 10-K
[ ] Transition Report on Form 20-F
[ ] Transition Report on Form 11-K
[ ] Transition Report on Form 10-Q
[ ] Transition Report on Form N-SAR
For the Transition Period Ended ________________
Nothing in this form shall be construed to imply that
the Commission has verified any information contained herein.
If the notification relates to a portion of the filing
checked above, identify the Item(s) to which the notification relates:
PART I - REGISTRANT INFORMATION
| Full Name of Registrant: |
Nu-Med Plus, Inc. |
| Former Name if Applicable: |
N/A |
|
Address of Principal
Executive Office: |
640 Belle Terre Rd. 2 E.
Port Jefferson, NY 11777 |
PART II - RULES 12b-25 (b) and (c)
If the subject report could not be filed without unreasonable effort or
expense, and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate) [X]
(a) The reasons described in reasonable detail in Part
III of this form could not be eliminated without unreasonable effort or expense;
(b) The subject annual report, semi-annual report,
transition report on Form 10-K, Form 20-F, Form 11-K, Form N-SAR or Form N-CSR, or portion thereof, will be filed on or before the fifteenth
calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q, or portion thereof
will be filed on or before the fifth calendar day following the prescribed due date.
(c) The accountant's statement or other exhibit required
by Rule 12b-25(c) has been attached if applicable.
PART III - NARRATIVE
The Company is in the process of completing its
unaudited financial statements, and believes that the subject Quarterly Report will be available for filing on or before August 19,
2024.
PART IV - OTHER INFORMATION
(1) Name and address of person to contact in regard
to this notification:
William R. Colvin
640 Belle Terre Rd. 2 E
Port Jefferson, NY 11777
Telephone: (631) 403-4337
(2) Have all other periodic reports required under
Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12
months or for such shorter period that the Registrant was required to file such report(s) been filed?
If the answer is no, identify report(s). [X] Yes [ ] No
(3) Is it anticipated that any significant change in
results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included
in the subject report or portion thereof?
[ ] Yes [X] No
If so, attach an explanation of the anticipated change,
both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.
NU-MED PLUS, INC. has caused this notification to be
signed on its behalf by the undersigned hereunto duly authorized.
Date: August 14, 2024
By/s/William R. Colvin
William R. Colvin, Chief Executive Officer and President